AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12801736 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal (50 g every 6 hours for 3 days)
Number of subjects: 401
Study 12801736 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 401
Study 12801736 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal
Number of subjects: 401
Study 12801736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 11192146 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 to 12 mg/d
Number of subjects: 1475
Study 11192146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1475
Study 9238896 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Tartar Control dentifrice
Number of subjects: 0
Study 9238896 — intervention group
Group type: COMPARATOR
Intervention: Crest Regular non-tartar control dentifrice
Number of subjects: 0
Study 1484579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 525
Study 1484579 — intervention group
Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 525
Study 2862297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triazolam 0.5 mg
Number of subjects: 60
Study 2862297 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 60
Study 2862297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29717362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon sutures
Number of subjects: 0
Study 29717362 — intervention group
Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 0
Study 29717362 — intervention group
Group type: COMPARATOR
Intervention: Coated polyglactin sutures
Number of subjects: 0
Study 29717362 — intervention group
Group type: COMPARATOR
Intervention: Polyester sutures
Number of subjects: 0
Study 29527973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (barbers encouraged meetings with specialty-trained pharmacists who prescribed drug therapy)
Number of subjects: 319
Study 29527973 — intervention group
Group type: COMPARATOR
Intervention: Active control (barbers encouraged lifestyle modification and doctor appointments)
Number of subjects: 319
Study 27114512 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (12 sessions targeting temporal structure learning using triple meter in music)
Number of subjects: 2
Study 27114512 — intervention group
Group type: COMPARATOR
Intervention: Play control (12 sessions of multimodal, social, repetitive play without music)
Number of subjects: 2
Study 25214778 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg
Number of subjects: 40
Study 25214778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21605879 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208
Study 21605879 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 208
Study 21605879 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 208
Study 21605879 — intervention group
Group type: EXPERIMENTAL
Intervention: HF unit
Number of subjects: 208
Study 21070705 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted formocresol (DFC)
Number of subjects: 152
Study 21070705 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray mineral trioxide aggregate (GMTA)
Number of subjects: 152
Study 17478265 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions (5 to 12 sessions) and school interventions (11 to 15 sessions) for 6th and 7th graders
Number of subjects: 28
Study 17478265 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interventions
Number of subjects: 28
Study 16275807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2 g/d)
Number of subjects: 65
Study 16275807 — intervention group
Group type: COMPARATOR
Intervention: D-serine (2 g/d)
Number of subjects: 65
Study 16275807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 12175391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic graft replacement (circular reinforced PTFE and Dacron silver grafts) after resection of inferior vena cava (IVC) and iliofemoral vein.
Number of subjects: 7
Study 12175391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic graft replacement after aggressive venous surgery for complete tumor resection.
Number of subjects: 7
Study 9458208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 141
Study 7869442 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 40
Study 7869442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1695304 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg b.i.d.
Number of subjects: 86
Study 1695304 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg b.i.d.
Number of subjects: 86
Study 1695304 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg b.i.d.
Number of subjects: 86
Study 1695304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 366145 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment
Number of subjects: 0
Study 366145 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro levamisole added to lymphocyte culture prior to drug treatment
Number of subjects: 0
Study 31680493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus magnesium sulfate
Number of subjects: 120
Study 31680493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus hydrocortisone
Number of subjects: 120
Study 31680493 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate plus hydrocortisone
Number of subjects: 120
Study 31680493 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 120
Study 31479863 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 22
Study 31479863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28716815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks + paclitaxel
Number of subjects: 728
Study 28716815 — intervention group
Group type: COMPARATOR
Intervention: Placebo + paclitaxel
Number of subjects: 728
Study 28716815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks
Number of subjects: 728
Study 28716815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study 25736164 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 11 mg/kg every 3 weeks
Number of subjects: 79
Study 25736164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23751377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-randomization 3D real time review (RTR)
Number of subjects: 340
Study 23751377 — intervention group
Group type: COMPARATOR
Intervention: Post-randomization 2D real time review (RTR)
Number of subjects: 340
Study 21272712 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy plus physical therapy (MET plus PT)
Number of subjects: 76
Study 21272712 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 76
Study 19794165 — intervention group
Group type: EXPERIMENTAL
Intervention: Double bundle anterior cruciate ligament reconstruction
Number of subjects: 200
Study 19794165 — intervention group
Group type: COMPARATOR
Intervention: Single bundle using Endobutton for femoral fixation
Number of subjects: 200
Study 19794165 — intervention group
Group type: COMPARATOR
Intervention: Single bundle using RigidFix cross pins for femoral fixation
Number of subjects: 200
Study 19794165 — intervention group
Group type: COMPARATOR
Intervention: Single bundle using bioabsorbable TransFix II screw for femoral fixation
Number of subjects: 200
Study 16533338 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture positive for Mycoplasma genitalium (group 1)
Number of subjects: 390
Study 16533338 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction-positive women (group 2)
Number of subjects: 390
Study 16533338 — intervention group
Group type: COMPARATOR
Intervention: Negative control women
Number of subjects: 390
Study 12622238 — intervention group
Group type: COMPARATOR
Intervention: Food additive containing vitamin C, vitamin E, ubiquinone (Q10), vitamin A, and zinc oxide for four weeks
Number of subjects: 48
Study 10228117 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP; 250 microgram twice a day)
Number of subjects: 30
Study 10228117 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (Sb; 400 microgram twice a day)
Number of subjects: 30
Study 8912948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of meta-chlorophenylpiperazine (MCPP) at a dose of 0.06 mg/kg
Number of subjects: 19
Study 8912948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1864106 — intervention group
Group type: EXPERIMENTAL
Intervention: Leak of 2.0 mm internal diameter (ID) and 37 mm length (Ringqvist's leak)
Number of subjects: 70
Study 1864106 — intervention group
Group type: EXPERIMENTAL
Intervention: Leak of 1.0 mm internal diameter (ID) and 15 mm length (Clausen's leak)
Number of subjects: 70
Study 1864106 — intervention group
Group type: COMPARATOR
Intervention: No leak
Number of subjects: 70
Study 6419710 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin
Number of subjects: 216
Study 6419710 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenbutazone/acetylsalicylic acid
Number of subjects: 216
Study 30658658 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies identified through an online survey and interviews at VAMCs.
Number of subjects: 40
Study 30658658 — intervention group
Group type: COMPARATOR
Intervention: Case reviews for patients identified by the STORM tool.
Number of subjects: 40
Study 30547490 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counselling by GPs
Number of subjects: 3640
Study 30547490 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with GPs
Number of subjects: 3640
Study 30547490 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit triage process by GPs
Number of subjects: 3640
Study 24798350 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg) combined with methotrexate (MTX) therapy, administered at weeks 0, 2, 6, and 14.
Number of subjects: 104
Study 24798350 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy (Control group).
Number of subjects: 104
Study 23789705 — intervention group
Group type: EXPERIMENTAL
Intervention: T100 PARI (150 mg/1.5 mL) nebulized with a PARI eFlow nebulizer
Number of subjects: 78
Study 23789705 — intervention group
Group type: COMPARATOR
Intervention: TOBI (300 mg/5 mL) nebulized with a PARI LC PLUS nebulizer
Number of subjects: 78
Study 22412171 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitatory theta burst stimulation (TBS) to the ipsilesional hemisphere
Number of subjects: 41
Study 22412171 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory theta burst stimulation (TBS) to the contralesional hemisphere
Number of subjects: 41
Study 22412171 — intervention group
Group type: COMPARATOR
Intervention: Sham TBS
Number of subjects: 41
Study 18720474 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 41
Study 16685253 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) 40 to 60 mg orally
Number of subjects: 12
Study 15078394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic advisory device replacement recommended for ICD implanted for secondary prevention
Number of subjects: 162
Study 15078394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic advisory device replacement recommended for pacemaker dependence
Number of subjects: 162
Study 15078394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic advisory device replacement recommended for prior appropriate ICD therapy
Number of subjects: 162
Study 15078394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic advisory device replacement recommended for higher likelihood of device malfunction
Number of subjects: 162
Study 15078394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic advisory device replacement recommended for physicians in practice <10 years
Number of subjects: 162
Study 12452391 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide
Number of subjects: 12
Study 12452391 — intervention group
Group type: COMPARATOR
Intervention: Balloon placement
Number of subjects: 12
Study 10572343 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 7
Study 10572343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7798068 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.25 mg once daily for 8 weeks
Number of subjects: 378
Study 7798068 — intervention group
Group type: COMPARATOR
Intervention: Indapamide 2.5 mg once daily for 8 weeks
Number of subjects: 378
Study 7798068 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1.25 mg
Number of subjects: 378
Study 7798068 — intervention group
Group type: COMPARATOR
Intervention: Indapamide 2.5 mg
Number of subjects: 378
Study 2750695 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (3 g)
Number of subjects: 8
Study 2750695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g lactose)
Number of subjects: 8
Study 776880 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% methenamine in a firm stick gel, applied daily to one palmar or plantar surface
Number of subjects: 109
Study 776880 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 109
Study 31233906 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over VMPFC
Number of subjects: 60
Study 31233906 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over rTPJ
Number of subjects: 60
Study 31233906 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 28739344 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol, probucol, or both
Number of subjects: 0
Study 25501785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel Ag
Number of subjects: 29
Study 25501785 — intervention group
Group type: COMPARATOR
Intervention: Xeroform
Number of subjects: 29
Study 23657891 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS+E
Number of subjects: 106
Study 23657891 — intervention group
Group type: COMPARATOR
Intervention: TIPS
Number of subjects: 106
Study 22169724 — intervention group
Group type: EXPERIMENTAL
Intervention: Three stages of 5-aminolevulinic acid-photodynamic therapy (ALA-PDT)
Number of subjects: 56
Study 19439137 — intervention group
Group type: EXPERIMENTAL
Intervention: Krakow end-to-end suturing technique (Group 1)
Number of subjects: 40
Study 19439137 — intervention group
Group type: COMPARATOR
Intervention: Minimal invasive repair with Achillon suture system (Group 2)
Number of subjects: 40
Study 17431366 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of prulifloxacin (600 mg) before the operation
Number of subjects: 432
Study 17431366 — intervention group
Group type: COMPARATOR
Intervention: 5-day course of prulifloxacin
Number of subjects: 432
Study 15148065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d)
Number of subjects: 28
Study 15148065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11717015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (10(6) kallikrein inhibitory units (KIU) loading dose followed by the same dose during chest closure)
Number of subjects: 103
Study 9219164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril, 10 mg by mouth daily (treated group)
Number of subjects: 20
Study 9219164 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study 7632200 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Behavior Checklist (CBCL) scores
Number of subjects: 890
Study 2972054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (240 micrograms, 40 micrograms each nostril, repeated twice at 15 min intervals)
Number of subjects: 8
Study 2972054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4599766 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 41
Study 4599766 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 41
Study 4599766 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 41
Study 31276460 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenon bupivacaine 0.5%
Number of subjects: 42
Study 31276460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27206914 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid treatment
Number of subjects: 20
Study 27206914 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% PAA treatment
Number of subjects: 20
Study 27206914 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA treatment
Number of subjects: 20
Study 27206914 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 20
Study 25231091 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg peramivir
Number of subjects: 12
Study 25231091 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg peramivir
Number of subjects: 12
Study 23609340 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 302
Study 23609340 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study 21467283 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/d
Number of subjects: 10739
Study 18523440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/day plant sterols in margarine divided equally at each of the three daily meals (three times per day)
Number of subjects: 19
Study 18523440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/day plant sterols in margarine with breakfast (single-BF)
Number of subjects: 19
Study 18523440 — intervention group
Group type: COMPARATOR
Intervention: Control margarine with each meal
Number of subjects: 19
Study 18523440 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 18523440 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-BF
Number of subjects: 19
Study 18523440 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times per day
Number of subjects: 19
Study 21656058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 500
Study 21656058 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 500
Study 21656058 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum mothers
Number of subjects: 500
Study 16005107 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training and supervision by a clinical nurse specialist for catheter care in the intervention group (42 participants).
Number of subjects: 82
Study 16005107 — intervention group
Group type: COMPARATOR
Intervention: Standard CVC procedures carried out by nurses in the control group (40 participants).
Number of subjects: 82
Study 12430668 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-reduced (PR) RBCs
Number of subjects: 597
Study 12430668 — intervention group
Group type: COMPARATOR
Intervention: Buffy coat-depleted (BCD) RBCs
Number of subjects: 597
Study 12430668 — intervention group
Group type: COMPARATOR
Intervention: WBC-filtered (WCF) RBCs
Number of subjects: 597
Study 9799203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine load (0.1 g/kg)
Number of subjects: 24
Study 9345462 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta-1a (IFN-beta-1a) 6.0 x 10(6) IU (30 micrograms) administered by weekly intramuscular injections
Number of subjects: 301
Study 9345462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 9345462 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta-1a (IFN-beta-1a)
Number of subjects: 301
Study 2694049 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autografting technique
Number of subjects: 35
Study 2694049 — intervention group
Group type: COMPARATOR
Intervention: Bare sclera technique (Control)
Number of subjects: 35
Study 742817 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated hypertensive patients
Number of subjects: 34
Study 742817 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypertensive patients
Number of subjects: 34
Study 742817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treated and untreated patients
Number of subjects: 34
Study 11522101 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I
Number of subjects: 168
Study 11522101 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 168
Study 11522101 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 168
Study 30872067 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention (add-on to existing disease management program)
Number of subjects: 495
Study 30872067 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 495
Study 30872067 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management intervention (for female participants)
Number of subjects: 495
Study 30872067 — intervention group
Group type: COMPARATOR
Intervention: Standard care (for female participants)
Number of subjects: 495
Study 29851157 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based orthopaedic care platform
Number of subjects: 400
Study 29851157 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 400
Study 26011792 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient uterine polypectomy
Number of subjects: 507
Study 26011792 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 507
Study 24953046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy with rosuvastatin
Number of subjects: 177
Study 24953046 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with pravastatin
Number of subjects: 177